The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Police looking to speak to a woman involved in an incident in Stephenville this morning
Staff at Corner Brook city hall concerned about unpaid taxes and mail delivery
Port of Corner Brook opens new warehouse to support regular container shipping to overseas markets
Lark Harbour man charged after police find cocaine, cash, pills and a taser
